Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent ≥ grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016). Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781).
Abstract
Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent ≥ grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016). Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781).
참고문헌 (30)
- Coiffier B, "Long-term outcome of patients in the LNH-98. 5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d’Etudes des Lymphomes de l’Adulte", Blood, 116, pp.2040~2045 (2010)
- Pfreundschuh M, "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial(MInT)Group", Lancet Oncol, 7, pp.379~391 (2006)
- Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60)", Lancet Oncol, 9, pp.105~116 (2008)
- Pfreundschuh M, "Prognostic significance of maximum tumour(bulk)diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab : an exploratory analysis of the MabThera International Trial Group(MInT)study", Lancet Oncol, 9, pp.435~444 (2008)
- Yoo KH, "Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma(CISL)trial", Int J Hematol, 107, pp.395~404 (2018)
- Stiff PJ, "Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 369, pp.1681~1690 (2013)
- Muller C, "The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL", Blood, 119, pp.3276~3284 (2012)
- 서철원, "The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective", Blood Research, 52(1), pp.3~6 (2017), 대한혈액학회
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Delarue R, "Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma(the LNH03-6B study) : a randomised phase 3 trial", Lancet Oncol, 14, pp.525~533 (2013)
- Pfreundschuh M, "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial(MInT)Group", Lancet Oncol, 12, pp.1013~1022 (2011)
- Leonard JP, "Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma", J Clin Oncol, 35, pp.3538~3546 (2017)
- Seymour JF, "R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma : final MAIN study outcomes", Haematologica, 99, pp.1343~1349 (2014)
- Nowakowski GS, "Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma : a phase II study", J Clin Oncol, 33, pp.251~257 (2015)
- Younes A, "Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma", J Clin Oncol, 37, pp.1285~1295 (2019)
- Pfreundschuh M, "Optimization of rituximab for the treatment of diffuse large B-cell lymphoma(II) : extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group", J Clin Oncol, 32, pp.4127~4133 (2014)
- Murawski N, "Optimization of rituximab for the treatment of DLBCL(I) : dose-dense rituximab in the DENSER-CHOP-14 trial of the DSHNHL", Ann Oncol, 25, pp.1800~1806 (2014)
- Lugtenburg PJ, "Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma : a randomized phase III trial of the HOVON and the Nordic Lymphoma Group(HOVON-84)", J Clin Oncol, 38, pp.3377~3387 (2020)
- Gleeson M, "Prognostic indices in diffuse large B-cell lymphoma in the rituximab era : an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21phase 3 trial", Br J Haematol, 192, pp.1015~1019 (2021)
- Xueying Li, "Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial", Cancer Research and Treatment, 51(3), pp.919~932 (2019), 대한암학회
- Cunningham D, "Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles", Lancet, 381, pp.1817~1826 (2013)
- Ohmachi K, "A randomized phase 2", 3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL : the JCOG0601 trial, 2021, pp.5, 984~993
- Hedstrom G, "Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma : a Swedish population-based study", Acta Oncol, 54, pp.924~932 (2015)
- Pfreundschuh M, "Suboptimal dosing of rituximab in male and female patients with DLBCL", Blood, 123, pp.640~646 (2014)
- Cook MB, "Sex disparities in cancer mortality and survival", Cancer Epidemiol Biomarkers Prev, 20, pp.1629~1637 (2011)
- Micheli A, "The advantage of women in cancer survival : an analysis of EUROCARE-4 data", Eur J Cancer, 45, pp.1017~1027 (2009)
- Riihijarvi S, "Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy", Eur J Haematol, 86, pp.124~128 (2011)
- Pfreundschuh M, "Increased rituximab(R)doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas : results from the SEXIE-R-CHOP-14 trial of the DSHNHL", J Clin Oncol, 32(15 Suppl), pp.8501~ (2014)
- Tilly H, "Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma", N Engl J Med, 386, pp.351~363 (2022)